<DOC>
	<DOCNO>NCT01723891</DOCNO>
	<brief_summary>Study compare safety pharmacokinetic property surfolase capsule HT-002-01 oral administration one day healthy male volunteer .</brief_summary>
	<brief_title>Study To Compare Safety Pharmacokinetic Properties Surfolase Capsule HT-002-01 Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>1. healthy male subject age 20 55 year body mass index 18.5 25 2 . Volunteers without apriority chronic disease 3 . Volunteers must good health determine investigator base detailed medical history , full physical examination , electrocardiogram , laboratory test urinalysis 4 . Volunteers comply protocol , understand sign inform consent 1 . Sensitive response acebrophylline xanthine 2 . Galactose intolerance , Lapp lactase deficiency GlucoseGalactose Malabsorption 3 . Known history renal , hepatic , respiratory , neurologic , endocrine , cardiac vascular hematopoietic disease , especially gallstone 4 . Known history gastrointestinal disease affect absorption medicine . 5 . Excluded screening test 6 . Upper limit AST , ALT &gt; 1.25 time Upper limit total bilirubin &gt; 1.5 time 7 . Estimated GFR &lt; 80mL/min/1.73m2 ) 8. systolic blood pressure &lt; 90 &gt; 150 , diastolic blood pressure &lt; 50 &gt; 100 9 . Known history drug abuse 10. caffeine &gt; 5cups/day , alcohol &gt; 210g/week , 10 cigarettes/day 11 . Use prescription drug within 14days overthecounter ( OTC ) medication within 7 day prior dose 12 . Participation clinical investigation within 60 day prior study start 13 . Donation blood within 60 day , donation component blood within 30days 14 . Judged investigator undesirable subject</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>